Bioprocessing supplies market to hit $12.35B by 2030

The global bioprocessing supplies market is forecast to grow from $10.31 billion in 2025 to $12.35 billion by 2030, driven by biologics, biosimilars, and cell and gene therapy manufacturing. North America led in 2025, while Asia-Pacific is expected to grow fastest as biomanufacturing expands.

Why it matters: - Bioprocessing supplies are essential to making biologic drugs, vaccines and advanced therapies at scale. - Demand is rising as drugmakers expand biologics, biosimilars and cell and gene therapy production. - The market forecast points to steady growth, not a spike, which signals durable demand for consumables and single-use systems.

What happened: - The Business Research Company said the global bioprocessing supplies market was valued at $10.31 billion in 2025 and is expected to reach $10.73 billion in 2026. - The report projects the market will climb to $12.35 billion by 2030. - The forecast implies a 4.0% CAGR from 2025 to 2026 and 3.6% CAGR from 2026 to 2030. - The report is titled “Bioprocessing Supplies Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035.” - A free sample report is available here. - The full market report is available here.

The details: - Bioprocessing supplies include the materials and consumables used in controlled environments for biological production. - The supplies help preserve process integrity, sterility and consistency in biomanufacturing. - The historical growth drivers included biologics and vaccine manufacturing, disposable bioprocess systems, outsourcing to contract manufacturing organizations, contamination-free production standards and GMP rules for bioprocess materials. - The 2030 outlook is supported by demand for personalized medicine and sophisticated biologics. - Cell and gene therapy manufacturing pipelines are increasing the need for specialized consumables. - Investments in localized biomanufacturing supply chains are expected to support growth. - Sustainable, recyclable bioprocess materials are emerging as a theme in the market. - Scalable single-use technologies are gaining traction in industrial bioproduction. - The report highlights standardization of single-use consumables, demand for pre-sterilized and gamma-irradiated supplies, cold chain-compatible materials, regulatory-compliant disposable packaging and local raw material sourcing.

Between the lines: - The market outlook suggests biomanufacturing is becoming more specialized and more dependent on standardized, contamination-resistant inputs. - The emphasis on localization reflects ongoing concern about supply-chain disruptions and raw material availability. - The move toward recyclable and disposable materials shows a tension between sustainability goals and the need for sterile, scalable production. - In January 2023, Cardinal Health said the FDA had approved 33 biosimilar products in the US by January 2022, with 21 commercially available, and that the totals rose to 40 approved biosimilars and 25 on the market by 2023.

What's next: - Bioprocessing suppliers are likely to benefit from broader adoption of personalized therapies and cell and gene manufacturing. - Asia-Pacific is projected to be the fastest-growing regional market as biomanufacturing infrastructure expands. - The report says North America held the largest share in 2025. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

The bottom line: - Bioprocessing supplies are on track for steady global growth through 2030 as biologics manufacturing becomes more complex and more widespread.